2025-02-28 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Review

**0. Key Figures Overview:**

VRTX has significantly outperformed the S&P 500 (VOO) over the analyzed period.  While the provided data doesn't specify the time frame, the cumulative return is substantially higher than the benchmark.  Recent price action shows some short-term weakness, but longer-term indicators suggest continued potential.


**1. Performance Comparison & Alpha/Beta Analysis:**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines.

* **Cumulative Return (VRTX):** 168.29%
* **Cumulative Return (VOO):** 112.87%
* **Return Difference:** 55.42%  (This represents a significant outperformance of VRTX compared to VOO.)
* **Relative Divergence:** 76.1% (This indicates VRTX's performance is in the upper quartile of its historical performance relative to VOO).

The Alpha/Beta analysis shows consistently positive alpha, indicating outperformance relative to the market (beta).  However, the Beta fluctuates, suggesting varying levels of market sensitivity over the years.  The high CAGR (Compound Annual Growth Rate) values, especially in the 2017-2019 period, showcase periods of exceptional growth. The negative CAGR in 2019-2021 highlights the impact of market fluctuations and potential sector-specific headwinds.  Market capitalization (Cap(B)) shows consistent growth, indicating expansion of the company.


**2. Recent Price Action:**

* **Closing Price:** $474.5
* **5-Day Moving Average:** $479.97
* **20-Day Moving Average:** $470.28
* **60-Day Moving Average:** $445.51

The price is currently below its 5-day moving average, suggesting a short-term bearish trend. However, it's above both the 20-day and 60-day moving averages, indicating a potentially supportive longer-term trend. The recent price drop of -$4.6 from the previous close (-0.96%) signals a minor pullback.


**3. Technical Indicators & Expected Return:**

* **RSI (Relative Strength Index):** 45.69 (Slightly below neutral, suggesting neither overbought nor oversold conditions.)
* **PPO (Price Oscillator):** -0.0344 (Negative value indicates bearish momentum in the short term.)
* **20-Day Relative Divergence Change:** +3.8% (Short-term upward trend.)
* **Expected Return (2+ years):** 15.7% (This represents a significant outperformance compared to the expected return of the S&P 500 over the long term.)

The relatively small price drop, combined with positive relative divergence and a long-term expected return, suggests the recent dip may be a buying opportunity for long-term investors.


**4. Recent Earnings Analysis:**

The earnings data shows volatility.  While Q1 2024 and Q3 2024 show strong EPS, Q2 2024 shows a substantial loss. Revenue shows steady growth, but profitability is affected by earnings inconsistencies. Further investigation is needed to understand the reason for the Q2 2024 EPS loss. Note: Duplicate entry for 2024-11-05 is present in the data.


| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-11-05 | $4.05  | $2.77B      |
| 2024-08-02 | -$13.92 | $2.65B      |
| 2024-05-07 | $4.26  | $2.69B      |
| 2023-11-07 | $4.01  | $2.48B      |


**5. Financial Information:**

Revenue is consistently increasing, with high and stable profit margins.  However, Equity and ROE (Return on Equity) show volatility, particularly a significant negative ROE in Q2 2024, mirroring the EPS loss.  This requires further investigation to understand the underlying causes.  Overall financial health seems strong, but specific quarter-to-quarter fluctuations require closer scrutiny.


| Quarter     | Revenue  | Profit Margin | Equity   | ROE     |
|-------------|----------|---------------|----------|---------|
| 2024-12-31 | $2.91B   | 85.46%        | $16.41B  | 5.56%   |
| 2024-09-30 | $2.77B   | 85.84%        | $15.63B  | 6.69%   |
| 2024-06-30 | $2.65B   | 85.94%        | $14.77B  | -24.32% |
| 2024-03-31 | $2.69B   | 87.27%        | $18.55B  | 5.93%   |
| 2023-12-31 | $2.52B   | 85.38%        | $17.58B  | 5.51%   |


**6. Overall Analysis:**

VRTX shows a strong long-term performance history significantly outperforming the S&P 500.  While recent price action indicates a short-term dip, the longer-term trends remain positive.  The high expected return, coupled with positive long-term moving averages, suggests potential for continued growth.  However, the volatility observed in quarterly earnings and ROE warrants further investigation into the underlying drivers of this fluctuation.  Investors should carefully consider the risks associated with the pharmaceutical sector and the company's specific operational factors before making any investment decisions.  A thorough review of the company's financial statements, strategic plans, and future product pipeline is recommended.
